Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok(Chinese University of Hong Kong), Masahiro Fukuoka(National Institute of Standards and Technology), Patrapim Sunpaweravong(Prince of Songkla University), Haiyi Jiang(AstraZeneca (Japan)), Emma Duffield(AstraZeneca (United Kingdom)), Yuichiro Ohe(National Cancer Center), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Baohui Han(Shanghai Chest Hospital), Busyamas Chewaskulyong(Maharaj Nakorn Chiang Mai Hospital), Yutaka Nishiwaki(National Cancer Center Hospital East), Jin-Ji Yang(Guangdong General Hospital), Da-Tong Chu(Chinese Academy of Medical Sciences & Peking Union Medical College), Benjamin Margono(Universitas Dr. Soetomo), Yukito Ichinose(National Hospital Organization Kyushu Cancer Center), Nagahiro Saijo(National Cancer Center Hospital East), Claire Watkins(AstraZeneca (United Kingdom)), Alison Armour(AstraZeneca (United Kingdom)), Sumitra Thongprasert(Chiang Mai University)
Cited by 8,241
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k